Heart Failure Research Institute

Advancing the understanding, prevention, and treatment of heart failure through research

Our Research

Our world-renowned experts, including physicians and scholars from Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons, are on the leading edge of heart failure research. 

Discover our latest publications, areas of interest, and how we’re advancing the field.

physician doing research

Download the NYP Advances App

Stay up to date with the NYP Advances app which brings together the latest updates in heart failure with expert reviews of clinical trials, conference series, and ongoing research from NewYork-Presbyterian experts.

Download the NYP App in the App Store 

NYP Advances App

Recent Publications

Amyloidosis

Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy. 

Lang FM, Teruya S, Cuomo M,
Santos AM, Radhakrishnan J, Lentzsch S, Chakraborty R, Bhutani D, Maurer MS. J Card Fail 2024
Dec;30(12):1641-1646. doi: 10.1016/j.cardfail.2024.06.009. Epub 2024 Jul 10. PMID: 38997000.


Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the
HELIOS-B Trial. 

Fontana M, Maurer MS, Gillmore JD, Bender S, Aldinc E, Eraly SA, Jay PY, Solomon SD. J Am
Coll Cardiol 2024 Nov 18:S0735-1097(24)10464-0. doi: 10.1016/j.jacc.2024.11.015. Online ahead of print. PMID:
39566871.


Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the
ATTRibute-CM Trial. 

Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, GarcíaPavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah
K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Circulation
2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072771. Online ahead of print. PMID: 39556242.


Coronary angiography-derived microvascular assessment (IMR angio) in patients with amyloidosis: a first US
report. 

Ha ET, Ramasubbu K, Alishetti S, Attallah M, Parikh MA, Kobayashi Y. Coron Artery Dis 2024 Dec
1;35(8):699-700. doi: 10.1097/MCA.0000000000001426. Epub 2024 Sep 27. PMID: 39324976.


Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical
implications. 

Noory N, Westin O, Maurer MS, Fosbøl E, Gustafsson F. Am Heart J 2025 Feb:280:52-59. doi:
10.1016/j.ahj.2024.11.004. Epub 2024 Nov 15. PMID: 39549982.


Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery. 

Noory N, Westin O, Fosbøl E, Maurer MS, Gustafsson F. Int J Cardiol 024 Nov 15:415:132469. doi:
10.1016/j.ijcard.2024.132469. Epub 2024 Aug 22. PMID: 39181411.


Differential Association of Transthyretin Stability with Variant and Wild-Type Transthyretin Amyloid
Cardiomyopathy: The SCAN-MP Study. 

Urina-Jassir M, Teruya S, Blaner WS, Brun PJ, Prokaeva T, Tsai FJ,
Kelly JW, Maurer MS, Ruberg FL. JACC Heart Fail 2024 Dec;12(12):2113-2115. doi: 10.1016/j.jchf.2024.06.014.
Epub 2024 Aug 7. PMID: 39115519.


Unlocking Diversity in Cardiovascular Clinical Research: Lessons from the Screening for Cardiac Amyloidosis
With Nuclear Imaging in a Minority Populations Study. 

Wardhere A, Bampatsias D, Cohn E, Fine D, Freitas C,
Gallegos C, Helmke S, Ionescu N, Ivrose J, Rodriguez C, Sabogal N, Fils S, Henry T, Teruya S, Ullah I, Kurian D,
Raiszadeh F, Miller EJ, Ruberg FL, Maurer MS. J Card Fail 2024 Nov;30(11):1507-1511. doi:
10.1016/j.cardfail.2024.04.019. Epub 2024 May 11. PMID: 38740174.


Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL
amyloidosis. 

Bazarbachi AH, Bhutani D, Radhakrishnan J, Mapara M, Maurer MS, Lentzsch S, Chakraborty R.
Am J Hematol 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115.


Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy. 

Zeldin L, Eichler JBS, Teruya SL, Weinsaft AY, Mirabal A, Cuomo MO, Mateo K, Helmke S, Maurer MS. Eur J Heart Fail 2024 Dec 5.doi: 10.1002/ejhf.3540. Online ahead of print. PMID: 39638976.


Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac
Amyloidosis. 

Miller P, Elias P, Einstein AJ, Maurer MS, Ahmed GY, Poterucha TJ. Circ Heart Fail 2024
Dec;17(12):e012075. doi: 10.1161/CIRCHEARTFAILURE.124.012075. Epub 2024 Nov 7. PMID: 39508097.


Glaucoma is not seen at a higher prevalence in age-related transthyretin amyloidosis after race stratification.

Estrada-Merly N, Maurer MS, D'Souza A. Amyloid 2024 Dec;31(4):339-341. doi:
10.1080/13506129.2024.2379394. Epub 2024 Jul 14. PMID: 39004806.


The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin
Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study.

Chan N, Einstein AJ, Teruya S, Rodriguez C, Helmke S, Cuomo M, Santana D, Castillo M, Smiley D, Sabogal N,
Lamour S, Winburn M, Fine D, de Freitas C, Kattan CG, Miller EJ, Maurer MS, Ruberg FL. Am J Cardiol 025 Feb
15:237:60-64. doi: 10.1016/j.amjcard.2024.11.019. Epub 2024 Nov 23. PMID: 39581521.


Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health-Related Quality of Life, and
Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis. 

Folkvaljon F, Gertz M, Gillmore JD, Khella S, Masri A, Maurer MS, Cruz MW, Wixner J, Chen J, Reicher B, Kwoh J, Yarlas A, Berk JL. Muscle Nerve 2025 Jan;71(1):96-107. doi: 10.1002/mus.28299. Epub 2024 Nov 17. PMID: 39552102.


Personalized Accelerated Physiologic Dual Rate Pacing for Cardiac Amyloidosis. 

Meyer M, Maharaj V, Nandy S,
Cogswell R, van Berlo JH, Maurer MS, Von Wald L, Roukoz H. JACC Case Rep 2024 Nov 20;29(22):102665. doi:
10.1016/j.jaccas.2024.102665. PMID: 39691881. 

Heart failure

Acute Cardiorenal Syndrome: An Update. 

Sohal S, Uppal D, Mathai SV, Wats K, Uppal NN. Cardiol Rev. 2024
Nov-Dec;32(6):489-498. doi: 10.1097/CRD.0000000000000532. Epub 2023 Mar 8. PMID: 36883827.


Extracellular vesicle therapeutics for cardiac repair. 

Hu Y, Zhang W, Ali SR, Takeda K, Vahl TP, Zhu D, Hong Y,
Cheng K. J Mol Cell Cardiol 2025 Feb:199:12-32. doi: 10.1016/j.yjmcc.2024.11.005. Epub 2024 Nov 26. PMID:39603560.


Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The
REBALANCE-HF Randomized Clinical Trial.

Fudim M, Borlaug BA, Mohan RC, Price MJ, Fail P, Goyal P, Hummel SL, Zirakashvili T, Shaburishvili T, Patel RB, Reddy VY, Nielsen CD, Chetcuti SJ, Sukul D, Gulati R, Kim L, Benzuly K, Mitter SS, Klein L, Uriel N, Augostini RS, Blair JE, Rocha-Singh K, Burkhoff D, Patel MR, Somo SI, Litwin SE, Shah SJ. JAMA Cardiol 2024 Dec 1;9(12):1143-1153. doi:10.1001/jamacardio.2024.2612. PMID:39356530.


Discontinuation versus continuation of statins: A systematic review. 

Peixoto C, Choudhri Y, Francoeur S, McCarthy LM, Fung C, Dowlatshahi D, Lemay G, Barry A, Goyal P, Pan J, Bjerre LM, Thompson W. J Am Geriatr Soc 2024 Nov;72(11):3567-3587. doi: 10.1111/jgs.19093. Epub 2024 Jul 25. PMID: 39051828.


Peak VO2: An old-school prognostic metric for all heart failure seasons

Colombo PC, Yuzefpolskaya M. J Heart Lung Transplant 2025 Feb;44(2):246-248. doi: 10.1016/j.healun.2024.11.015. Epub 2024 Nov 17. PMID: 39561863.


Reductions in renin-angiotensin system inhibitors following hospitalization for heart failure. 

Goyal P, Chen L, Lau JD, Rosenson RS, Levitan EB. ESC Heart Fail 2024 Dec;11(6):3862-3871. doi: 10.1002/ehf2.14953. Epub 2024 Jul PMID: 39030944.


Extracellular Matrix Instability and Chronic Inflammation Underlie Maladaptive Right Ventricular Pressure Overload
Remodeling and Failure in Male Mice. 

Russo I, Dun W, Mehta S, Ahmed S, Tzimas C, Fukuma N, Tsai EJ. Am J Physiol Heart Circ Physiol 2024 Dec 16. doi: 10.1152/ajpheart.00331.2024. Online ahead of print. PMID: 39679492.


Perceptions About Diversity, Equity, and Inclusion Among Cardiovascular Fellows-in-Training. 

Duqueney E, DeFilippis EM, Goyal A, Kaur G, Julien H, Eberly L. J Am Heart Assoc 2024 Dec 17;13(24):e036955. doi:
10.1161/JAHA.124.036955. Epub 2024 Nov 11. PMID: 39527007.


Emergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart Failure.
Casey MF, Hallmark J, Chang PP, Rodgers JE, Mehta A, Chari SV, Skersick P, Bohrmann T, Goyal P, Meyer ML.
Drug Saf 2024 Dec;47(12):1225-1234. doi: 10.1007/s40264-024-01479-5. Epub 2024 Sep 12. PMID: 39264483.


The Cumulative Burden of Social Risk Factors and 10-Year Change in Quality of Life. Reid RJ, Safford M, Lambert
WM, Bryan J, Pinheiro LC, Sterling MR, Bowling CB, Levitan EB, Banerjee S, Durant R, Kim M, Lau JD, Goyal P.
J Gerontol A Biol Sci Med Sci 2024 Dec 11;80(1):glae222. doi: 10.1093/gerona/glae222. PMID: 39749982.


Comparison of Physical Frailty Assessments in Heart Failure With Preserved Ejection Fraction. 

Zainul O, Marshall D, Lau JD, Kelly B, Zarzuela K, Damluji A, Pandey A, Pastva AM, Goyal P. JACC Adv 2024 Dec
26;3(12):101395. doi: 10.1016/j.jacadv.2024.101395. eCollection 2024 Dec. PMID: 39736919.


Hierarchical endpoints analyzed using the win-ratio method as a practical innovation for deprescribing trials.
Goyal P, Banerjee S, Steinman MA, Ambrosy AP. J Am Geriatr Soc 2024 Oct 17. doi: 10.1111/jgs.19224. Online
ahead of print. PMID: 39417389.


ExCITe: A Narrative Review of Motivating Factors for Residency and Fellowship Selection to Provide Insights
Regarding the Waning Interest in Advanced Heart Failure and Transplant Cardiology Training. 

Zitelny E, Drazner MH, Davis J, Reza N, Defilippis EM, Khazanie P, Teerlink JR, Kataria R. J Card Fail 2024 Nov 20:S1071-
9164(24)00930-8. doi: 10.1016/j.cardfail.2024.10.443. Online ahead of print. PMID: 39577738.


Dietary Interventions in Heart Failure With Preserved Ejection Fraction: A Scoping Review. 

Billingsley HE, Carbone S, Driggin E, Kitzman DW, Hummel SL. JACC Adv 2024 Dec 17;4(1):101465. doi:
10.1016/j.jacadv.2024.101465. eCollection 2025 Jan. PMID: 39801812.

Heart transplantation


Efficacy and safety of belatacept in heart transplant recipients

Baranowska J, Oren D, Valledor AF, Uriel M, Lee C, Moeller CM, Elad B, Rahman S, Hertz A, Skoll D, Regan M, DeFilippis EM, Raikhelkar J, Fried J, Lotan D, Oh KT, Bae D, Rahman A, Choe J, Clerkin K, Yunis AA, Yuzefpolskaya M, Colombo PC, Majure D, Latif F, Sayer G, Uriel N. Efficacy and safety of belatacept in heart transplant recipients. J Heart Lung Transplant. 2025 Oct;44(10):1612-1620. doi: 10.1016/j.healun.2025.04.023. Epub 2025 May 28. PMID: 40446881.


Sarcopenia Assessment Using Fully Automated Deep Learning Predicts Cardiac Allograft Survival in Heart Transplant Recipients 

Lang FM, Liu J, Clerkin KJ, Driggin EA, Einstein AJ, Sayer GT, Takeda K, Uriel N, Summers RM, Topkara VK. Sarcopenia Assessment Using Fully Automated Deep Learning Predicts Cardiac Allograft Survival in Heart Transplant Recipients. Circ Heart Fail. 2025 Oct;18(10):e012805. doi: 10.1161/CIRCHEARTFAILURE.125.012805. Epub 2025 Aug 20. PMID: 40832698.


Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single-Center Experience

Rubinstein G, Valledor AF, Moeller CM, Baranowska J, Oren D, Oh DKT, Bae D, Yunis A, Lotan D, Rahman A, Raikhelkar JK, Fried JA, DeFilippis EM, Clerkin KJ, Latif F, Sayer GT, Uriel N. Extracorporeal Photopheresis in the Treatment of Cardiac Allograft Rejection in the Modern Era: A Single-Center Experience. Clin Transplant. 2025 Aug;39(8):e70247. doi: 10.1111/ctr.70247. PMID: 40698560.


Screening and Surveillance for Colorectal Cancer Before and After Heart Transplantation 

Abrams ME, Keller E, Lemos C, Regan M, O'Connell DC, Salgado SM, Donald E, Salazar R, Hennecken C, Raikhelkar JK, Latif F, Clerkin KJ, Sayer G, Uriel N, DeFilippis EM. Screening and Surveillance for Colorectal Cancer Before and After Heart Transplantation. Clin Transplant. 2025 Sep;39(9):e70301. doi: 10.1111/ctr.70301. PMID: 40965853.


Correlation between donor-derived cell-free DNA and tissue gene expression in heart transplant patients undergoing for-cause endomyocardial biopsies

Valledor AF, Moeller CM, Oren D, Baranowska J, Rahman S, Hertz A, Rahman A, Hennecken C, Rubinstein G, Elad B, Richter I, Lotan D, Regan M, LaBarre B, Yunis A, Fried J, DeFilippis EM, Colombo PC, Yuzefpolskaya M, Raihkelkar J, Latif F, Clerkin KD, Majure DT, Sayer GT, Uriel N. Correlation between donor-derived cell-free DNA and tissue gene expression in heart transplant patients undergoing for-cause endomyocardial biopsies. J Heart Lung Transplant. 2025 Sep;44(9):1384-1393. doi: 10.1016/j.healun.2025.04.019. Epub 2025 May 13. PMID: 40374050.


Outcomes After Heart Transplantation Among Non-Native English-Speaking Recipients

Vargas F, Batra J, Lemos C, Magun E, Salazar RA, Taylor CN, Donald EM, Driggin E, Regan M, McArthur-Murphy R, Lumish H, Concha D, Chung A, Golob S, Latif F, Clerkin KJ, Takeda K, Sayer G, Uriel N, Defilippis EM. Outcomes After Heart Transplantation Among Non-Native English-Speaking Recipients. J Card Fail. 2025 Oct;31(10):1534-1543. doi: 10.1016/j.cardfail.2024.12.010. Epub 2025 Jan 20. PMID: 39842708.


Clinical Utility of Combined Donor-Derived Cell-Free DNA and Peripheral Gene-Expression-Profiling in Heart Transplant Recipients 

Moeller CM, Valledor AF, Oren D, Rahman S, Rahman A, Regan M, Lee C, Hertz A, Rubinstein G, Baranowska J, Elad B, Hennecken C, Salazar R, Oren A, Donald EM, Lotan D, Oh KT, Bae D, Yunis A, Majure D, Yuzefpolskaya M, Colombo PC, Raikhelkar JK, Fried JA, DeFilippis EM, Takeda K, Clerkin KJ, Latif F, Sayer GT, Uriel N. Clinical Utility of Combined Donor-Derived Cell-Free DNA and Peripheral Gene-Expression-Profiling in Heart Transplant Recipients. Clin Transplant. 2025 Oct;39(10):e70340. doi: 10.1111/ctr.70340. PMID: 41085484.


Impact of Donor and Recipient Sex-Mismatch in Donation After Circulatory Death Heart Transplant

Rajesh K, Feng I, Latif F, Sayer G, Uriel N, Kaku Y, Naka Y, Kurlansky P, Takeda K. Impact of Donor and Recipient Sex-Mismatch in Donation After Circulatory Death Heart Transplant. Clin Transplant. 2025 Sep;39(9):e70285. doi: 10.1111/ctr.70285. PMID: 40891331.


Significance of Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Negative Endomyocardial Biopsies: A Dawn of a New Era

Moeller CM, Fernandez Valledor A, Oren D, Rahman S, Baranowska J, Hertz A, DeFilippis EM, Lee C, Regan M, Oren A, Rahman A, Hennecken C, Salazar R, Donald EM, Lotan D, Majure D, Yuzefpolskaya M, Colombo PC, Raikhelkar JK, Fried JA, Clerkin KJ, Latif F, Sayer GT, Uriel N. Significance of Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients With Negative Endomyocardial Biopsies: A Dawn of a New Era. Circ Heart Fail. 2025 Sep 30:e012787. doi: 10.1161/CIRCHEARTFAILURE.125.012787. Epub ahead of print. PMID: 41025234.


Comparable short-term survival in dual organ heart transplant recipients with and without HIV: A call for increased access to organ donation for people living with HIV

Donald EM, Batra J, DeFilippis EM, Raikhelkar JK, Lotan D, Clerkin KJ, Sayer G, Uriel N. Comparable short-term survival in dual organ heart transplant recipients with and without HIV: A call for increased access to organ donation for people living with HIV. Am J Transplant. 2025 Sep;25(9):1996-2007. doi: 10.1016/j.ajt.2025.05.004. Epub 2025 May 7. PMID: 40345498.


Sex Differences in Utilization of Donation After Circulatory Death Donors for Heart Transplantation and Associated Outcomes

DeFilippis EM, Masotti M, Donald EM, Eichler J, Ramu B, Watt T, Mulvihill MS, Takeda K, Uriel N, Cogswell R. Sex Differences in Utilization of Donation After Circulatory Death Donors for Heart Transplantation and Associated Outcomes. Circ Heart Fail. 2025 Aug;18(8):e012835. doi: 10.1161/CIRCHEARTFAILURE.125.012835. Epub 2025 Jun 26. PMID: 40567220.


Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia

Orlando EH, Gould P, Cuzzo B, Ford M, Chen Y, Sanjurjo A, Jain S, May B, Tsapepas D, Leeman-Neill RJ, Bhagat G, Dube GK, Morris H, Arcasoy S, Latif F, DeFilippis EM, Martinez M, Im GY, Phipps MM, Pereira MR, Sue PK, Orjuela-Grimm M, Lipsky AH, Sawas A, Reshef R, Pro B, Cherng HJ, Amengual JE. Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia. Blood Neoplasia. 2025 Aug 19;2(4):100160. doi: 10.1016/j.bneo.2025.100160. PMID: 41127866; PMCID: PMC12538014.


Surveillance Patterns for Allograft Vasculopathy in Heart Transplant Recipients in PET Myocardial Perfusion Imaging Performing Centers in the United States

Feher A, Alwan M, Wright CX, Clerkin KJ, Einstein AJ, Miller EJ, Al-Mallah MH. Surveillance Patterns for Allograft Vasculopathy in Heart Transplant Recipients in PET Myocardial Perfusion Imaging Performing Centers in the United States. JACC Heart Fail. 2025 Oct 14:102718. doi: 10.1016/j.jchf.2025.102718. Epub ahead of print. PMID: 41099687.

Cardiogenic shock & mechanical circulatory support

Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis

Kanwar MK, Uriel N, Carnicelli A, John K, Li S, Kong C, Zweck E, Sinha SS, Ton VK, Garan AR, Kataria R, Abraham J, Hernandez-Montfort J, Burkhoff D; CSWG Academic Research Consortium; Kapur NK. Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis. J Heart Lung Transplant. 2025 Oct;44(10):1583-1594. doi: 10.1016/j.healun.2025.05.017. Epub 2025 Jun 29. PMID: 40592372.


Impact of comorbidity burden on outcome in patients with cardiogenic shock: A Cardiogenic Shock Working Group analysis

Sundermeyer J, Li S, Ton VK, Kataria R, Zweck E, John K, Kanwar MK, Hernandez-Montfort J, Sinha SS, Garan AR, Abraham J, Blumer V, Kochar A, Ranganathan K, Hickey GW, Pahuja M, Lundgren S, Nathan S, Vorovich E, Hall S, Khalife W, Schwartzman A, Kim J, Vishnevsky OA, Fried J, Farr M, Mishkin J, Chang IH, Ilonze O, Arias A, Nakata J, Marbach J, Bezerra H, Gage A, Wald J, Thomas S, Rahman F, Masoumi A, Afsal A, Gohar S, Goodman R, Walec KD, Natov P, Li B, Sangal P, Kong Q, Zazzali P, Harwani NM, Vallabhajosyula S, Bhimaraj A, Mahr C, Burkhoff D, Kapur NK. Impact of comorbidity burden on outcome in patients with cardiogenic shock: A Cardiogenic Shock Working Group analysis. Eur J Heart Fail. 2025 Sep 16. doi: 10.1002/ejhf.70017. Epub ahead of print. PMID: 40956069.


Liberal or restrictive transfusion for veno-arterial extracorporeal membrane oxygenation patients: a target trial emulation using the OBLEX study data

Thao LTP, Buscher H, Nguyen TL, Martucci G, Gratz J, Trummer G, Schmidt M, Gautier M, Serra A, Takeda K, Pooth JS, Rahn K, Geismann F, Lubnow M, Retter A, Nair P, Vlok R, Siriwardena M, Winearls J, Walsham J, Gattas D, Aneman A, Fulcher B, Newman S, Reynolds C, Arcadipane A, Shekar K, Hodgson C, Pellegrino V, Mueller T, Brodie D, McQuilten Z; International ECMO Network (ECMONet). Liberal or restrictive transfusion for veno-arterial extracorporeal membrane oxygenation patients: a target trial emulation using the OBLEX study data. Crit Care. 2025 Aug 18;29(1):360. doi: 10.1186/s13054-025-05606-1. PMID: 40826421; PMCID: PMC12359932.


Impella 5.5 use in women: A multicenter study 

Asher M, Rekhtman D, Iyengar A, DePaolo J, Song C, Feng I, Morganroth E, Dardik G, Shin M, Weingarten N, Brown A, Wald J, Biscotti M, Takeda K, Cevasco M. Impella 5.5 use in women: A multicenter study. JHLT Open. 2025 Jul 10;9:100341. doi: 10.1016/j.jhlto.2025.100341. PMID: 40778211; PMCID: PMC12329075.


Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support

Feng I, Powley TR, Yang CG, Kurlansky PA, Sutherland LD, Hastie JM, Kaku Y, Fried JA, Takeda K. Unfractionated heparin monitoring by anti-factor Xa versus activated partial thromboplastin time strategies during venoarterial extracorporeal life support. Perfusion. 2025 Oct;40(7):1575-1584. doi: 10.1177/02676591241309500. Epub 2024 Dec 26. PMID: 39724911.
 

Comparison of Heart Failure Cardiogenic Shock Patients with Axillary and Femoral Intra-aortic Balloon Pump: Cardiogenic Shock Working Group report

Bhimaraj A, Garan AR, Kong Q, Kim JU, Pahuja M, Kochar A, Narayangowda S, Li B, Li S, Sinha SS, Hickey GW, Kataria R, Ton VK, Lundgren S, Nathan S, Vorovich E, Hall S, Khalife W, Schwartzman A, Vishnevsky OA, Zweck E, Fried J, Farr MJ, Mahr C, Mishkin J, Chiang IH, Ilonze O, Arias A, Marbach J, Bezerra H, Sangal P, Walec KD, Zazzali P, Harwani NM, Blumer V, John K, Hernandez-Montfort J, Abraham J, Burkhoff D, Kanwar MK, Kapur NK. Comparison of Heart Failure Cardiogenic Shock Patients with Axillary and Femoral Intra-aortic Balloon Pump: Cardiogenic Shock Working Group report. J Card Fail. 2025 Aug 20:S1071-9164(25)00364-1. doi: 10.1016/j.cardfail.2025.07.020. Epub ahead of print. PMID: 40846302.


Early Extracorporeal Membrane Oxygenation Initiation May Improve Outcomes in Select Patients With Primary Pulmonary Hypertension: An Extracorporeal Life Support Organization Registry Analysis

Smood B, Vasquez CR, Olia SE, Han JJ, Iyengar A, Patrick WL, Helmers MR, Kelly JJ, Richards T, Usman A, Cantu E 3rd, Takeda K, Langer N, Cevasco M. Early Extracorporeal Membrane Oxygenation Initiation May Improve Outcomes in Select Patients With Primary Pulmonary Hypertension: An Extracorporeal Life Support Organization Registry Analysis. ASAIO J. 2025 Aug 1;71(8):611-620. doi: 10.1097/MAT.0000000000002390. Epub 2025 Feb 18. PMID: 39963975; PMCID: PMC12310370.

Pulmonary hypertension

Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension.

Reddy YNV, Frantz RP, Hassoun PM, Hemnes AR, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill
NS, Erzurum SC, Beck GJ, Finet JE, Jellis CL, Mathai SC, Tang WHW, Borlaug BA. J Am Coll Cardiol 2024
Nov 26;84(22):2196-2210. doi: 10.1016/j.jacc.2024.08.061. Epub 2024 Oct 23. PMID: 39453363.


Non-invasive prediction of pulmonary vascular disease-related exercise intolerance and survival in nongroup 1 pulmonary hypertension

Reddy YNV, Dubrock H, Hassoun PM, Hemnes A, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Mathai SC, Mukherjee M, Tang WHW, Borlaug BA, Frantz RP; and the PVDOMICS Study Group Eur J Heart Fail 2024 Nov;26(11):2323-2336. doi:10.1002/ejhf.3396. Epub 2024 Jul 26. PMID: 39058211.


Alterations in Mitochondrial Function in Pulmonary Vascular Diseases. 

Farha S, Asosingh K, Hassoun PM, Barnard J, Comhair S, Reichard A, Wanner N, Radeva M, Aldred MA, Beck GJ, Berman-Rosenzweig E, Borlaug BA, Finet JE, Frantz RP, Grunig G, Hemnes AR, Hill N, Horn EM, Jellis C, Leopold JA, Mehra R,
Park MM, Rischard FP, Tang WHW, Erzurum SC; PVDOMICS Study Group. Antioxid Redox Signal 2024 Dec 10. doi: 10.1089/ars.2024.0557. Online ahead of print. PMID: 39655485.


SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation.
Frantz RP, Desai SS, Ewald G, Franco V, Hage A, Horn EM, LaRue SJ, Mathier MA, Mandras S, Park MH,
Ravichandran AK, Schilling JD, Wang IW, Zolty R, Rendon GG, Rocco MA, Selej M, Zhao C, Rame JE. Pulm Circ
2024 Dec 4;14(4):e12446. doi: 10.1002/pul2.12446. eCollection 2024 Oct. PMID: 39635465.


High Pulmonary Hypertension Risk by Echocardiogram Shortens Survival in Polycythemia Vera. Gazda AJ, Pan D,
Erdos K, Abu-Zeinah G, Racanelli A, Horn EM, Scandura JM. Blood Adv 2024 Dec 18:bloodadvances.2024013970.
doi: 10.1182/bloodadvances.2024013970. Online ahead of print. PMID: 39693509.

Hypertrophic cardiomyopathy

Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in
Hypertrophic Cardiomyopathy. 

Lumish HS, Sherrid MV, Janssen PML, Ferrari G, Hasegawa K, Castillero E,
Adlestein E, Swistel DG, Topkara VK, Maurer MS, Reilly MP, Shimada YJ. J Am Coll Cardiol 2024 Nov
12;84(20):1999-2011. doi: 10.1016/j.jacc.2024.07.043. Epub 2024 Oct 2. PMID: 39365226.


Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics
profiling. 

Lumish HS, Harano N, Liang LW, Hasegawa K, Maurer MS, Tower-Rader A, Fifer MA, Reilly MP, Shimada
YJ. Europace 2024 Nov 1;26(11):euae267. doi: 10.1093/europace/euae267. PMID: 39441047.


Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy
from Other Cardiomyopathies with Left Ventricular Hypertrophy. 

Akita K, Maurer MS, Tower-Rader A, Fifer MA,
Shimada YJ. Circ Heart Fail 2025 Jan;18(1):e012434. doi: 10.1161/CIRCHEARTFAILURE.124.012434. Epub 2024
Nov 11. PMID: 39523983.


Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning. 

Lu R, Lumish HS, Hasegawa K, Maurer MS, Reilly MP, Weiner SD, Tower-Rader A, Fifer MA, Shimada YJ. Eur J Heart
Fail 2024 Nov 1;26(11):euae267. doi: 10.1093/europace/euae267. PMID: 39694602.

Other topics

What Factors Facilitate Successful Participation in Digital Home-Based Cardiac Rehabilitation?

Elad B, Ben-Gal S, Elias A, Promyslovsky M, Eisen I, Caspi O. J Cardiopulm Rehabil Prev 2025 Jan 1;45(1):72-74. doi:
10.1097/HCR.0000000000000909. Epub 2024 Nov 19. PMID: 39746000.


Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers. 

Shetty NS, Gaonkar M, Pampana A, Patel N, Morrison AC, Reiner AP, Carson AP, Yu B, Psaty BM, Kooperberg C, Fatkin D, Boerwinkle E, Rotter JI, Taylor KD, Hou L, Irvin MR, Hall ME, Maurer M, Fornage M, Armstrong ND, Bart N, Goyal P, Rich SS, Vasan RS, Li P, Arora G, Arora P. JACC Heart Fail 2025 Jan;13(1):91-101. doi: 10.1016/j.jchf.2024.08.019. Epub 2024 Nov 6. PMID: 39520444.